Targeting glutamine metabolism in myeloproliferative neoplasms

Blood Cells, Molecules, and Diseases

Volumn 55, Issue 3, 2015, Pages 241-247

  Zhan, Huichun ^a,b   Ciano, Kristen ^a   Dong, Katherine ^c   Zucker, Stanley ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer metabolism; Glutaminase inhibitor; Glutamine; JAK2 inhibitor; Myeloproliferative neoplasm

Indexed keywords

BIS 2 (5 PHENYLACETAMIDO 1,3,4 THIADIAZOL 2 YL)ETHYL SULFIDE; GLUTAMINASE; GLUTAMINE; HYDROLASE INHIBITOR; JANUS KINASE 2; OXYGEN; PHENYLALANINE; RUXOLITINIB; UNCLASSIFIED DRUG; VALINE; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ACIDIFICATION; AMINO ACID METABOLISM; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG POTENTIATION; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MUTANT; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; OXYGEN CONSUMPTION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTHEMIA; UPREGULATION; WILD TYPE; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; TUMOR CELL LINE;

CELL LINE, TUMOR; GLUTAMINE; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PYRAZOLES; UP-REGULATION;

EID: 84937846256     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.07.007     Document Type: Article

References (46)

1. Kralovics R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352(17):1779-1790.
2. James C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148.
3. Levine R.L., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397.
4. Baxter E.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
5. Zhao R., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 2005, 280(24):22788-22792.
6. Jones A.V., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106(6):2162-2168.
7. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8(6):519-530.
8. Hensley C.T., Wasti A.T., DeBerardinis R.J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 2013, 123(9):3678-3684.
9. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science 1955, 122(3168):501-514.
10. Eagle H., et al. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J. Biol. Chem. 1956, 218(2):607-616.
11. Brosnan J.T. Interorgan amino acid transport and its regulation. J. Nutr. 2003, 133(6 Suppl 1):2068S-2072S.
12. Gao P., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458(7239):762-765.
13. Wise D.R., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(48):18782-18787.
14. DeBerardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29(3):313-324.
15. Le A., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15(1):110-121.
16. Dang C.V. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:369-374.
17. Mukherjee S. The Emperor of All Maladies: A Biography of Cancer 2010, Scribner, (ISBN-10: 1439170916).
18. Reddy M.M., et al. The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia 2012, 26(3):481-489.
19. Zhan H., et al. MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol. Dis. 2013, 50(3):190-195.
20. Etheridge S.L., et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 2014, 123(7):1059-1068.
21. Saur S.J., et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010, 115(6):1254-1263.
22. Ishii T., et al. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006, 108(9):3128-3134.
23. Xu X., et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 2007, 109(1):339-342.
24. DeBerardinis R.J., et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(49):19345-19350.
25. Xiang Y., et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 2015, 125(6):2293-2306.
26. Knox W.E., Horowitz M.L., Friedell G.H. The proportionality of glutaminase content to growth rate and morphology of rat neoplasms. Cancer Res. 1969, 29(3):669-680.
27. Linder-Horowitz M., Knox W.E., Morris H.P. Glutaminase activities and growth rates of rat hepatomas. Cancer Res. 1969, 29(6):1195-1199.
28. Perez-Gomez C., et al. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem. J. 2005, 386(Pt 3):535-542.
29. Robinson M.M., et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 2007, 406(3):407-414.
30. Wang J.B., et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18(3):207-219.
31. Campbell P.J., Green A.R. The myeloproliferative disorders. N. Engl. J. Med. 2006, 355(23):2452-2466.
32. Dupont S., et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007, 110(3):1013-1021.
33. Godfrey A.L., et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 2012, 120(13):2704-2707.
34. Stein B.L., et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010, 95(7):1090-1097.
35. Harrison C., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 2012, 366(9):787-798.
36. Verstovsek S., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 2012, 366(9):799-807.
37. Seltzer M.J., et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70(22):8981-8987.
38. Shukla K., et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 2012, 55(23):10551-10563.
39. Rampal R., et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014, 123(22):e123-e133.
40. Anand S., et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 2011, 118(6):1610-1621.
41. Wang X., et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood 2014, 124(19):2987-2995.
42. Klampfl T., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 2013, 369(25):2379-2390.
43. Nangalia J., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 2013, 369(25):2391-2405.
44. Gross M.I., et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 2014, 13(4):890-901.
45. van den Heuvel A.P., et al. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol. Ther. 2012, 13(12):1185-1194.
46. Emadi A., et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp. Hematol. 2014, 42(4):247-251.